Publications by authors named "Frances Blevins"

Claim this Profile
E
Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics.
Cameron S Fraser, Johan K E Spetz, Xingping Qin, Adam Presser, Jonathan Choiniere, Frances Blevins

Nat Commun· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis.
David M Hughes, Lynnette Henshaw, Frances Blevins, Camille Edwards, Adam Lerner

Clin Lymphoma Myeloma Leuk· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Underrepresentation of Black participants and adverse events in clinical trials of lenalidomide for myeloma.
Charles J Milrod, Michael Mann, Frances Blevins, David Hughes, Preya Patel

Crit Rev Oncol Hematol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series.
David M Hughes, Charina Toste, Christopher Nelson, Juliet Escalon, Frances Blevins

J Adv Pract Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs.
Charles J Milrod, Frances Blevins, David Hughes, Adam Lerner, Shayna Sarosiek

Blood· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis